In further sub-group analysis, GLP-1RA users were associated with a significantly lower risk of incident LC when compared to insulin users across all histological types, including squamous cell carcinoma (HR: 0.364, 95% CI: 0.168, 0.789), adenocarcinoma of the lung (HR: 0.509, 95% CI: 0.333, 0.778), large cell carcinoma (HR: 0.345, 95% CI: 0.124, 0.959), and small cell LC (SCLCL) (HR: 0.101, 95% CI: 0.013, 0.8) (Figure 2). The gene discussed is INS; the disease is lung adenocarcinoma.